Trial Outcomes & Findings for PRescriptiOn PattERns Of Oral Anticoagulants (NCT NCT02366338)
NCT ID: NCT02366338
Last Updated: 2015-05-21
Results Overview
Appropriateness of oral anticoagulants was evaluated by adapted versions of the MAI
Recruitment status
COMPLETED
Target enrollment
148 participants
Primary outcome timeframe
1 day
Results posted on
2015-05-21
Participant Flow
Participant milestones
| Measure |
Group 1
patients on warfarin therapy
|
Group 2
patients on rivaroxaban therapy
|
Group 3
Patients on dabigatran therapy
|
|---|---|---|---|
|
Overall Study
STARTED
|
73
|
39
|
36
|
|
Overall Study
COMPLETED
|
73
|
39
|
36
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
PRescriptiOn PattERns Of Oral Anticoagulants
Baseline characteristics by cohort
| Measure |
Group 1
n=73 Participants
patients on warfarin therapy
|
Group 2
n=39 Participants
patients on rivaroxaban therapy
|
Group 3
n=36 Participants
Patients on dabigatran therapy
|
Total
n=148 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
72 years
STANDARD_DEVIATION 9 • n=5 Participants
|
69 years
STANDARD_DEVIATION 9 • n=7 Participants
|
72 years
STANDARD_DEVIATION 8 • n=5 Participants
|
71 years
STANDARD_DEVIATION 9 • n=4 Participants
|
|
Sex: Female, Male
Female
|
42 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
20 Participants
n=5 Participants
|
84 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
31 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
16 Participants
n=5 Participants
|
64 Participants
n=4 Participants
|
|
Region of Enrollment
Turkey
|
73 participants
n=5 Participants
|
39 participants
n=7 Participants
|
36 participants
n=5 Participants
|
148 participants
n=4 Participants
|
PRIMARY outcome
Timeframe: 1 dayAppropriateness of oral anticoagulants was evaluated by adapted versions of the MAI
Outcome measures
| Measure |
Group 1
n=73 Participants
patients on warfarin therapy
|
Group 2
n=39 Participants
patients on rivaroxaban therapy
|
Group 3
n=36 Participants
Patients on dabigatran therapy
|
|---|---|---|---|
|
Number of Patients With at Least One Inappropriate MAI Criterion
|
61 participants
|
11 participants
|
17 participants
|
Adverse Events
Group 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Group 2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Group 3
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place